Shareholders' Equity - Additional Information (Details)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
8 Months Ended |
48 Months Ended |
50 Months Ended |
57 Months Ended |
|
|
Apr. 28, 2025
USD ($)
$ / shares
shares
|
Feb. 19, 2025
USD ($)
|
Jan. 31, 2025
USD ($)
shares
|
Dec. 10, 2024
USD ($)
|
Aug. 09, 2024
USD ($)
$ / shares
shares
|
Oct. 07, 2022
USD ($)
$ / shares
|
Feb. 12, 2021
$ / shares
shares
|
Feb. 10, 2021
$ / shares
shares
|
Feb. 08, 2021
$ / shares
shares
|
Oct. 31, 2020
$ / shares
shares
|
Oct. 27, 2020
$ / shares
shares
|
Jul. 02, 2020
$ / shares
shares
|
Jun. 05, 2020
$ / shares
shares
|
Jun. 03, 2020
$ / shares
shares
|
Apr. 27, 2018
USD ($)
$ / shares
shares
|
Apr. 22, 2025
USD ($)
shares
|
Oct. 31, 2020
USD ($)
$ / shares
shares
|
Jun. 30, 2020
$ / shares
shares
|
Mar. 31, 2025
USD ($)
Vote
$ / shares
shares
|
Mar. 31, 2024
USD ($)
|
Mar. 31, 2025
USD ($)
$ / shares
shares
|
Jan. 31, 2025
USD ($)
shares
|
Mar. 31, 2025
USD ($)
$ / shares
shares
|
Mar. 31, 2025
USD ($)
$ / shares
shares
|
Dec. 31, 2024
USD ($)
$ / shares
shares
|
May 03, 2023
$ / shares
shares
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase to authorized ordinary shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60,000,000
|
Ordinary shares, par value | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.01
|
|
$ 0.01
|
|
$ 0.01
|
$ 0.01
|
$ 0.01
|
$ 0.01
|
Aggregate offering price of shares | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 357,000
|
|
$ 357,000
|
|
$ 357,000
|
$ 357,000
|
$ 315,000
|
|
Ordinary shares, shares authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,000,000
|
|
80,000,000
|
|
80,000,000
|
80,000,000
|
80,000,000
|
|
Number of vote per common share | Vote |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
Common stock rights and preferences |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
There are no redemption or sinking fund provisions with respect to the authorized ordinary shares.
|
|
|
|
|
|
|
|
Authorized amount for sale of stock | $ |
|
$ 150,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares, shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35,686,616
|
|
35,686,616
|
|
35,686,616
|
35,686,616
|
31,534,233
|
|
Proceeds from registered direct offerings, net of transaction costs | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 6,357,000
|
$ 7,217,000
|
|
|
|
|
|
|
Aggregate principal amount of exchangeable notes | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 40,691,000
|
|
|
|
|
Accrued and unpaid interest | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,071,000
|
|
|
|
|
Undesignated preferred shares, par value | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.01
|
|
$ 0.01
|
|
$ 0.01
|
$ 0.01
|
$ 0.01
|
|
Undesignated preferred shares, authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000,000
|
|
100,000,000
|
|
100,000,000
|
100,000,000
|
100,000,000
|
|
Undesignated preferred shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
0
|
0
|
0
|
|
Sales Agreement With H.C. Wainwright |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares, par value | $ / shares |
|
|
|
|
|
$ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of ordinary shares sold |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,125,901
|
|
|
|
|
|
|
|
Offering price per ordinary share | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.59
|
|
$ 1.59
|
|
$ 1.59
|
$ 1.59
|
|
|
Proceeds from registered direct offerings, net of transaction costs | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 6,300,000
|
|
|
|
|
|
|
|
Subsequent Events |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares, shares issued |
3,040,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of ordinary shares sold |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
900,000
|
|
|
|
|
|
|
|
|
|
|
Aggregate gross proceeds from ordinary shares | $ |
$ 5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from registered direct offerings, net of transaction costs | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 957,000
|
|
|
|
|
|
|
|
|
|
|
Warrants to purchase ordinary shares, exercise price | $ / shares |
$ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum | Sales Agreement With H.C. Wainwright |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
May offer and sell ordinary shares for aggregate gross sales proceeds | $ |
|
|
|
|
|
$ 16,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
May offer and sell ordinary shares for additional aggregate offering price | $ |
|
|
|
$ 25,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loan and Security Agreement | Silicon Valley Bank (SVB) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loan and security agreement entered date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Apr. 27, 2018
|
|
|
|
|
|
|
|
Maximum amount available under agreement | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 30,000,000
|
|
|
|
|
|
|
|
|
|
|
|
Long-Term Line of Credit | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 15,000,000
|
|
|
|
|
|
|
|
|
|
|
|
2024 Rights Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subscription price per whole unit | $ / shares |
|
|
|
|
$ 1.21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate gross proceeds from rights offering | $ |
|
|
|
|
$ 7,400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate net proceeds from rights offering | $ |
|
|
|
|
$ 5,400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of units sold |
|
|
|
|
6,121,965
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
$ 1.21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Private Placement | Securities Purchase Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrants to purchase ordinary shares |
|
|
|
|
|
|
|
|
|
|
|
|
13,868
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
$ 31.5465
|
$ 24.3
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants expiry date |
|
|
|
|
|
|
|
|
|
|
|
|
Jun. 03, 2025
|
Dec. 05, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercisable date |
|
|
|
|
|
|
|
|
|
|
|
|
Jun. 03, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of ordinary shares issued to purchase warrants |
|
|
|
|
|
|
|
|
|
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Private Placement | Securities Purchase Agreement | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrants to purchase ordinary shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
99,057
|
|
|
|
|
|
|
|
|
|
|
|
|
Private Placement | June 30 SPA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrants to purchase ordinary shares |
|
|
|
|
|
|
|
|
|
|
|
15,739
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
$ 27.7965
|
|
|
|
|
|
$ 21.3
|
|
|
|
|
|
|
|
|
Warrants expiry date |
|
|
|
|
|
|
|
|
|
|
|
Jun. 30, 2025
|
|
|
|
|
|
Jan. 02, 2026
|
|
|
|
|
|
|
|
|
Percentage of ordinary shares issued to purchase warrants |
|
|
|
|
|
|
|
|
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from exercise of warrants related to registered direct offering | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,796,000
|
|
|
Warrants exercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
84,317
|
|
84,317
|
|
84,317
|
84,317
|
|
|
Private Placement | June 30 SPA | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrants to purchase ordinary shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
112,422
|
|
|
|
|
|
|
|
|
October Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from registered direct offerings, net of transaction costs | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 13,885,000
|
|
|
|
|
|
|
|
|
|
Number of warrants to purchase ordinary shares |
|
|
|
|
|
|
|
|
|
125,641
|
|
|
|
|
|
|
125,641
|
|
|
|
|
|
|
|
|
|
Number of warrants exercised for ordinary shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,392,701
|
|
1,392,701
|
|
1,392,701
|
1,392,701
|
|
|
Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
$ 12.1875
|
$ 9.75
|
|
|
|
|
|
$ 12.1875
|
|
|
|
|
|
|
|
|
|
Warrants expiry date |
|
|
|
|
|
|
|
|
|
Oct. 22, 2025
|
Oct. 27, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of ordinary shares issued to purchase warrants |
|
|
|
|
|
|
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
October Offering | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrants to purchase ordinary shares |
|
|
|
|
|
|
|
|
|
|
1,346,153
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
February Underwritten Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Offering closing date |
|
|
|
|
|
|
|
Feb. 10, 2021
|
Feb. 08, 2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional ordinary shares that can be purchased by underwriter |
|
|
|
|
|
|
|
347,826
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrants exercised for ordinary shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,333
|
|
25,333
|
|
25,333
|
25,333
|
|
|
Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
|
|
|
$ 21.5625
|
$ 21.5625
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants expiry date |
|
|
|
|
|
|
|
Feb. 03, 2026
|
Feb. 03, 2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of ordinary shares issued to purchase warrants |
|
|
|
|
|
|
|
7.00%
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from warrants connected to registered direct offerings | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 546,000
|
|
|
|
February Underwritten Offering | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrants to purchase ordinary shares |
|
|
|
|
|
|
|
24,347
|
162,318
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
February Registered Direct Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Offering closing date |
|
|
|
|
|
|
Feb. 12, 2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrants to purchase ordinary shares |
|
|
|
|
|
|
81,666
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
|
|
$ 37.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants expiry date |
|
|
|
|
|
|
Feb. 09, 2026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of ordinary shares issued to purchase warrants |
|
|
|
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants to Purchase 19,890 Ordinary Shares | Silicon Valley Bank and Life Sciences Fund II LLC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants expiry date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Apr. 27, 2028
|
|
|
|
|
|
|
|
|
|
|
|
1-Year Warrant | 2024 Rights Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares that can be purchased with each warrant |
|
|
|
|
0.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from registered direct offerings, net of transaction costs | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,040,000
|
|
|
|
|
|
Number of warrants to purchase ordinary shares |
|
|
|
|
3,060,982
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.21
|
|
$ 1.21
|
|
$ 1.21
|
$ 1.21
|
|
|
Warrants exercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
859,825
|
|
859,825
|
|
859,825
|
859,825
|
|
|
5-Year Warrants | 2024 Rights Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from registered direct offerings, net of transaction costs | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 804,000
|
|
|
|
|
|
Number of warrants to purchase ordinary shares |
|
|
|
|
6,121,965
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
$ 1.21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.21
|
|
$ 1.21
|
|
$ 1.21
|
$ 1.21
|
|
|
Warrants exercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
664,802
|
|
664,802
|
|
664,802
|
664,802
|
|
|
Series B Convertible Preferred Shares | Silicon Valley Bank and Life Sciences Fund II LLC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrants to purchase ordinary shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19,890
|
|
|
|
|
|
|
|
|
|
|
|
Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 282.75
|
|
|
|
|
|
|
|
|
|
|
|
Undesignated Preferred Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Undesignated preferred shares, par value | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.01
|
|
$ 0.01
|
|
$ 0.01
|
$ 0.01
|
|
|
Undesignated preferred shares, authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000,000
|
|
100,000,000
|
|
100,000,000
|
100,000,000
|
|
|
Designated Preferred Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Undesignated preferred shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
0
|
0
|
|
|
Ordinary Shares | Silicon Valley Bank and Life Sciences Fund II LLC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrants to purchase ordinary shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,326
|
|
|
|
|
|
|
|
|
|
|
|
Exchangeable Notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares, shares issued |
|
|
3,760,155
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,760,155
|
|
3,760,155
|
3,760,155
|
3,760,155
|
3,760,155
|
|
|
Aggregate principal amount of exchangeable notes | $ |
|
|
$ 11,117,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 40,691,000
|
|
|
|
|
Accrued and unpaid interest | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,071,000
|
|
|
|
|
Accrued interest | $ |
|
|
$ 3,628,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,628,000
|
|
|
|
|
Exchangeable Notes | Private Placement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class Of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of exchangeable notes | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 40,691,000
|
|
|
|
|